A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein.

Abstract excerpt

Drug resistance is of increasing concern, especially during the treatments of infectious diseases and cancer. To accelerate the drug discovery process in combating issues of drug resistance, here we developed a computational and experimental strategy to predict drug resistance mutations. Using BCR-ABL as a case study, we successfully recaptured the clinically observed mutations that confer resistance imatinib,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Algorithms
• Share to Antineoplastic Agents
• Share to Drug Discovery